Effexor en es it fr


Effexor Nombres de marca, Effexor Analogos

Effexor Marca los nombres de mezcla

  • No information avaliable
  • Effexor Formula quimica


    Effexor RX enlace


    Effexor FDA hoja

    Effexor FDA

    Effexor MSDS (hoja de seguridad de materiales)

    Effexor MSDS

    Effexor Sintesis de referencia

    Maridos GEM et al., Patente de EE.UU.. 4,535,186 (1985)

    Effexor Peso molecular

    277.402 g/mol

    Effexor Punto de fusion

    215-217oC (Hydrochloride salt)

    Effexor H2O Solubilidad

    572 mg / ml (clorhidrato)

    Effexor Estado


    Effexor LogP


    Effexor Formas de dosificacion

    Cápsulas (liberación sostenida)

    Effexor Indicacion

    Para el tratamiento de la depresión severa

    Effexor Farmacologia

    Venlafaxina, un antidepresivo estructuralmente relacionado con otros antidepresivos, se utiliza para tratar la melancolía, del trastorno de ansiedad generalizada (TAG), trastorno de pánico, trastorno por estrés postraumático, y los sofocos en las sobrevivientes de cáncer de mama.

    Effexor Absorcion

    No hay información disponible

    Effexor Toxicidad

    No hay información disponible

    Effexor Informacion de Pacientes

    Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with Effexor and should counsel them in its appropriate use. A patient Medication Guide About Using Antidepressants in Children and Teenagers is available for Effexor. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

    Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking Effexor.

    Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, other unusual changes in behavior, worsening of depression, and suicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to observe for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patientís prescriber or health professional, especially if they are severe, abrupt in onset, or were not part of the patientís presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and possibly changes in the medication.

    Interference with Cognitive and Motor Performance

    Clinical studies were performed to examine the effects of venlafaxine on behavioral performance of healthy individuals. The results revealed no clinically significant impairment of psychomotor, cognitive, or complex behavior performance. However, since any psychoactive drug may impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Effexor therapy does not adversely affect their ability to engage in such activities.


    Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.


    Patients should be advised to notify their physician if they are breast-feeding an infant.

    Concomitant Medication

    Patients should be advised to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, including herbal preparations, since there is a potential for interactions.


    Although Effexor has not been shown to increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking Effexor.

    Allergic Reactions

    Patients should be advised to notify their physician if they develop a rash, hives, or a related allergic phenomenon.

    Laboratory Tests

    There are no specific laboratory tests recommended.


    About Using Antidepressants in Children and Teenagers

    What is the most important information I should know if my child is being prescribed an antidepressant?

    Parents or guardians need to think about 4 important things when their child is prescribed an antidepressant:

    1. There is a risk of suicidal thoughts or actions.

    2. How to try to prevent suicidal thoughts or actions in your child.

    3. You should watch for certain signs if your child is taking an antidepressant.

    4. There are benefits and risks when using antidepressants.

    1. There is a Risk of Suicidal Thoughts or Actions

    Children and teenagers sometimes think about suicide, and many report trying to kill themselves.

    Antidepressants increase suicidal thoughts and actions in some children and teenagers. But suicidal thoughts and actions can also be caused by depression, a serious medical condition that is commonly treated with antidepressants. Thinking about killing yourself or trying to kill yourself is called suicidality or being suicidal.

    A large study combined the results of 24 different studies of children and teenagers with depression or other illnesses. In these studies, patients took either a placebo (sugar pill) or an antidepressant for 1 to 4 months. No one committed suicide in these studies, but some patients became suicidal. On sugar pills, 2 out of every 100 became suicidal. On the antidepressants, 4 out of every 100 patients became suicidal.

    For some children and teenagers, the risks of suicidal actions may be especially high. These include patients with:

    • Bipolar illness (sometimes called manic-depressive illness)
    • A family history of bipolar illness
    • A personal or family history of attempting suicide

    If any of these are present, make sure you tell your healthcare provider before your child takes an antidepressant.

    2. How to Try to Prevent Suicidal Thoughts and Actions

    To try to prevent suicidal thoughts and actions in your child, pay close attention to changes in her or his moods or actions, especially if the changes occur suddenly. Other important people in your childís life can help by paying attention as well (e.g., your child, brothers and sisters, teachers, and other important people). The changes to look out for are listed in Section 3, on what to watch for.

    Whenever an antidepressant is started or its dose is changed, pay close attention to your child.

    After starting an antidepressant, your child should generally see his or her healthcare provider:

    • Once a week for the first 4 weeks
    • Every 2 weeks for the next 4 weeks
    • After taking the antidepressant for 12 weeks
    • After 12 weeks, follow your healthcare providerís advice about how often to come back
    • More often if problems or questions arise

    You should call your childís healthcare provider between visits if needed.

    3. You Should Watch for Certain Signs If Your Child is Taking an Antidepressant

    Contact your childís healthcare provider right awayif your child exhibits any of the following signs for the first time, or if they seem worse, or worry you, your child, or your childís teacher:

    • Thoughts about suicide or dying
    • Attempts to commit suicide
    • New or worse depression
    • New or worse anxiety
    • Feeling very agitated or restless
    • Panic attacks
    • Difficulty sleeping (insomnia)
    • New or worse irritability
    • Acting aggressive, being angry, or violent
    • Acting on dangerous impulses
    • An extreme increase in activity and talking
    • Other unusual changes in behavior or mood

    Never let your child stop taking an antidepressant without first talking to his or her healthcare provider. Stopping an antidepressant suddenly can cause other symptoms.

    4. There are Benefits and Risks When Using Antidepressants

    Antidepressants are used to treat depression and other illnesses. Depression and other illnesses can lead to suicide. In some children and teenagers, treatment with an antidepressant increases suicidal thinking or actions. It is important to discuss all the risks of treating depression and also the risks of not treating it. You and your child should discuss all treatment choices with your healthcare provider, not just the use of antidepressants.

    Other side effects can occur with antidepressants.

    Of all the antidepressants, only fluoxetine (Prozac™ ) has been FDA approved to treat pediatric depression.

    For obsessive compulsive disorder in children and teenagers, FDA has approved only fluoxetine (Prozac™ ), sertraline (Zoloft™ ), fluvoxamine, and clomipramine (Anafranil™ ).*

    Your healthcare provider may suggest other antidepressants based on the past experience of your child or other family members.

    Is this all I need to know if my child is being prescribed an antidepressant?

    No. This is a warning about the risk for suicidality. Other side effects can occur with antidepressants. Be sure to ask your healthcare provider to explain all the side effects of the particular drug he or she is prescribing. Also ask about drugs to avoid when taking an antidepressant. Ask your healthcare provider or pharmacist where to find more information.

    *Prozac™ is a registered trademark of Eli Lilly and Company
    Zoloft™ is a registered trademark of Pfizer Pharmaceuticals
    Anafranil™ is a registered trademark of Mallinckrodt Inc.

    This Medication Guide has been approved by the U.S. Food and Drug Administration for all antidepressants.
    CI 8055-2W10402C011
    Rev 01/05
    Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101

    Effexor Organismos afectados

    Humanos y otros mamíferos